An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Celgene
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of lenalidomide and a proteosome inhibitor alone or in combination
Documented refractory or relapsed and refractory multiple myeloma
Refractory to proteosome inhibitor and lenalidomide, and to last treatment
Relapsed and refractory patients must have achieved at least a partial response to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months, and were refractory to their last treatment
Measurable disease at screening
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
You may not be if
Active plasma cell leukemia
Prior treatment with pomalidomide
Unable to tolerate thromboembolic prophylaxis while on the study
Prior autologous stem cell transplant within 12 weeks
Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
Clareo Health | An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
